bluebird bio announces that lentiviral vector BB305 is unlikely to be the cause of AML in clinical study of LentiGlobin for Sickle Cell Disease
Gene therapy for a subtype of eye disease approved in the Netherlands
From 2021, patients suffering from RPE65-associated retinal disease will be able to be treated in three UMCs of the Netherlands.
https://www.radboudumc.nl/nieuws/2020/gentherapie-voor-zeldzame-oogziekte-vergoed
Abstract submission and Greiner Award nominations
The deadline to submit the abstracts for the Annual Symposium 2020, as well as the nominations for the Greiner Award has been extended until January 31st.